The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

The presentation will be available on Azitra’s website at https://ir.azitrainc.com/news-events/presentations.

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

Astrazeneca Pharma India said that it has received permission from Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab solutions (IMFINZI) in India.